Top Markets
Coin of the day
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Rankning i aktier #14767
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Aktiekurs
$16.85
Senast synkroniserad: 2023-07-07
Marknadsvärde
$393.50M
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
CH
Handel VectivBio Holding AG (VECT)

Kategori

Aktiekurshistorik för VectivBio Holding AG (VECT)
Högsta slutkurs: $16.72 den 2023-07-01

Lägsta slutkurs: $16.68 den 2021-04-01
Aktiekurshistorik för VectivBio Holding AG från 2021 till 2026
Årlig aktiekursutveckling
År Prestanda
2023 96.64%
2022 112.95%
2021 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$745.22 4.45%
CH